We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

26 hedge funds and large institutions have $65.9M invested in SAB Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

4.53% more ownership

Funds ownership: 0% → 4.53% (+4.5%)

Holders
26
Holders Change
+26
Holders Change %
–
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Basso Capital Management
Connecticut
+$6.87M
2
PC
Periscope Capital
Ontario, Canada
+$6M
3
KIM
Karpus Investment Management
New York
+$5.95M
4
SCM
Shaolin Capital Management
Florida
+$5.2M
5
MP
Mangrove Partners
Connecticut
+$5.18M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
Basso Capital Management
Connecticut
$6.74M +$6.87M +68,674 New
PC
2
Periscope Capital
Ontario, Canada
$5.89M +$6M +60,000 New
KIM
3
Karpus Investment Management
New York
$5.84M +$5.95M +59,489 New
SCM
4
Shaolin Capital Management
Florida
$5.11M +$5.2M +52,026 New
MP
5
Mangrove Partners
Connecticut
$5.09M +$5.18M +51,838 New
Hudson Bay Capital Management
6
Hudson Bay Capital Management
Connecticut
$4.91M +$5M +50,000 New
PAMP
7
Polar Asset Management Partners
Ontario, Canada
$4.91M +$5M +50,000 New
FTCM
8
Fir Tree Capital Management
New York
$4.42M +$4.5M +45,000 New
HSBC Holdings
9
HSBC Holdings
United Kingdom
$3.7M +$3.74M +37,378 New
WRBC
10
W.R. Berkley Corp
Connecticut
$3.53M +$3.59M +35,927 New
RCM
11
Radcliffe Capital Management
Pennsylvania
$3.44M +$3.5M +35,000 New
PMAM
12
Picton Mahoney Asset Management
Ontario, Canada
$2.94M +$3M +30,000 New
MSU
13
Mizuho Securities USA
New York
$2.84M +$2.9M +28,992 New
WAM
14
Wolverine Asset Management
Illinois
$1.51M +$1.54M +15,381 New
SCM
15
Saba Capital Management
New York
$1.48M +$1.51M +15,065 New
RCM
16
Rivernorth Capital Management
Florida
$982K +$1,000K +10,000 New
Goldman Sachs
17
Goldman Sachs
New York
$721K +$734K +7,342 New
Citadel Advisors
18
Citadel Advisors
Florida
$452K +$461K +4,607 New
AA
19
AQR Arbitrage
Connecticut
$442K +$450K +4,500 New
JP Morgan Chase
20
JP Morgan Chase
New York
$264K +$269K +2,692 New
EAM
21
Exos Asset Management
New York
$246K +$250K +2,500 New
Jane Street
22
Jane Street
New York
$182K +$185K +1,855 New
WAM
23
Weiss Asset Management
Massachusetts
$100K +$102K +1,019 New
HighTower Advisors
24
HighTower Advisors
Illinois
$98K +$100K +1,000 New
UBS Group
25
UBS Group
Switzerland
$9K +$8.7K +87 New
1
2

SABS Hedge Fund Activity: Q1 2021 in Review

26 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2021, worth a combined $65.9M.

Buyers outnumbered sellers: 26 funds opened new SABS positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Basso Capital Management, opening a new position worth an estimated $6.87M.

  • 26 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $65.9M of SAB Biotherapeutics stock for Q1 2021.
  • 26 funds opened new SAB Biotherapeutics positions in Q1 2021 and 0 closed out, a net change of +26 holders.
  • The largest SAB Biotherapeutics buyer in Q1 2021 was Basso Capital Management, an estimated $6.87M added.

Based on aggregated 13F filings for Q1 2021.